Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro

被引：49
|
作者：
Gruber, A
Speth, C
Lukasser-Vogl, E
Zangerle, R
Borg-von Zepelin, M
Dierich, MP
Würzner, R
机构：
[1] Univ Innsbruck, Ludwig Boltzman Inst AIDS Forsch, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Inst Dermatol & Venereol, A-6020 Innsbruck, Austria
[3] Univ Gottingen, Inst Hyg, D-3400 Gottingen, Germany
来源：
IMMUNOPHARMACOLOGY | 1999年 / 41卷 / 03期
基金：
奥地利科学基金会;
关键词：
Candida albicans; Indinavir; HIV-1;
D O I：
10.1016/S0162-3109(99)00035-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The putative virulence factor secreted aspartyl proteinase (SAP) of Candida albicans and the human immunodeficiency virus type 1 (HIV-1) protease both belong to the aspartyl proteinase family. The present study demonstrates that the HIV-1 protease inhibitor Indinavir is a weak but specific inhibitor of SAP. In addition, Indinavir reduces the amount of cell bound as well as released SAP antigen from C. albicans. Furthermore, viability and growth of C. albicans are markedly reduced by Indinavir, These findings indicate that HIV-1 protease inhibitors may possess antifungal activity and we speculate that in vivo SAP inhibition may add to the resolution of mucosal candidiasis in HIV-1 infected subjects. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：227 / 234
页数：8
相关论文
共 50 条
  • [31] In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
    Carrillo, A
    Stewart, KD
    Sham, HL
    Norbeck, DW
    Kohlbrenner, WE
    Leonard, JM
    Kempf, DJ
    Molla, A
    JOURNAL OF VIROLOGY, 1998, 72 (09) : 7532 - 7541
  • [32] In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385
    Yates, PJ
    Hazen, R
    St Clair, M
    Boone, L
    Tisdale, M
    Elston, RC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 1092 - 1095
  • [33] Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients
    Baqui, AAMA
    Meiller, TF
    Falkler, WA
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1999, 6 (06) : 808 - 811
  • [34] Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
    Condra, JH
    Holder, DJ
    Schleif, WA
    Blahy, OM
    Danovich, RM
    Gabryelski, LJ
    Graham, DJ
    Laird, D
    Quintero, JC
    Rhodes, A
    Robbins, HL
    Roth, E
    Shivaprakash, M
    Yang, T
    Chodakewitz, JA
    Deutsch, PJ
    Leavitt, RY
    Massari, FE
    Mellors, JW
    Squires, KE
    Steigbigel, RT
    Teppler, H
    Emini, EA
    JOURNAL OF VIROLOGY, 1996, 70 (12) : 8270 - 8276
  • [35] Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease
    Ghosh, AK
    Pretzer, E
    Cho, H
    Hussain, KA
    Düzgünes, N
    ANTIVIRAL RESEARCH, 2002, 54 (01) : 29 - 36
  • [36] Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
    Condra, JH
    Petropoulos, CJ
    Ziermann, R
    Schleif, WA
    Shivaprakash, M
    Emini, EA
    JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (03): : 758 - 765
  • [37] Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence Polymorphisms within patients
    Poon, Art F. Y.
    Pond, Sergei L. Kosakovsky
    Richman, Douglas D.
    Frost, Simon D. W.
    JOURNAL OF VIROLOGY, 2007, 81 (24) : 13598 - 13607
  • [38] Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor
    Servais, J
    Lambert, C
    Fontaine, E
    Plesséria, JM
    Robert, I
    Arendt, V
    Staub, T
    Schneider, F
    Hemmer, R
    Burtonboy, G
    Schmit, JC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 893 - 900
  • [39] Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants
    Faye, A
    Bertone, C
    Teglas, JP
    Chaix, ML
    Douard, D
    Firtion, G
    Thuret, I
    Dollfus, C
    Monpoux, F
    Floch, C
    Nicolas, J
    Vilmer, E
    Rouzioux, C
    Mayaux, MJ
    Blanche, S
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (06) : 518 - 525
  • [40] Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission
    Pillay, K
    Coutsoudis, A
    Agadzi-Naqvi, AK
    Kuhn, L
    Coovadia, HM
    Janoff, EN
    JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (04): : 653 - 656
12345